Ramya et al., 2012 - Google Patents
L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemiaRamya et al., 2012
- Document ID
- 7953608763735776926
- Author
- Ramya L
- Doble M
- Rekha V
- Pulicherla K
- Publication year
- Publication venue
- Applied biochemistry and biotechnology
External Links
Snippet
Acute lymphoblastic leukaemia (ALL) is one of the leading types of malignant disorder seen in children. Viral infections, genetic factors and exposure to chemical carcinogens are some of the factors responsible for causing ALL. Treatment strategies followed for curing ALL …
- 102100004323 ASPG 0 title abstract description 140
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramya et al. | L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia | |
| Kumar et al. | L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia | |
| Shrivastava et al. | Recent developments in L-asparaginase discovery and its potential as anticancer agent | |
| US11845933B2 (en) | Structure-guided chemical modification of guide RNA and its applications | |
| Sorrentino | The eight human “canonical” ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins | |
| RU2480217C2 (en) | Use of isothiocyanate derivatives as anti-myeloma drugs | |
| US9803185B2 (en) | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein | |
| US5372942A (en) | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent | |
| CN101812438B (en) | Arginine deiminase mutant and preparation and application thereof | |
| Lukasheva et al. | L-lysine α-oxidase: enzyme with anticancer properties | |
| EP3186371B1 (en) | Administration of kynurenine depleting enzymes for tumor therapy | |
| Tosta Pérez et al. | L-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review | |
| Zhang et al. | Enhancing antitumor efficacy of nucleoside analog 5-fluorodeoxyuridine on HER2-overexpressing breast cancer by affibody-engineered DNA nanoparticle | |
| CN101016340A (en) | Fusion polypeptide and use thereof in treatment of tumor and cell growth abnormity correlated disease | |
| JP2023551482A (en) | PD-L1 binding peptides and peptide complexes and methods of using them | |
| Wang et al. | Gene cloning and expression of a novel hypoglycaemic peptide from Momordica charantia | |
| CN102863537A (en) | Tumor targeting tumor necrosis factor related apoptosis ligand variant and application thereof | |
| US9322008B2 (en) | Mutants of L-asparaginase | |
| Cho et al. | Tumor-specific monomethyl auristatin E (MMAE) prodrug nanoparticles for safe and effective chemotherapy | |
| EP3444351B1 (en) | Ribonucleic acid aptamer having inhibitory effect on non-small cell lung cancer, and pharmaceutical composition comprising same | |
| US8986683B2 (en) | Combined use of ribonuclease and artemisinin | |
| van der Sluis et al. | Pediatric acute lymphoblastic leukemia: efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia | |
| EP2654776A1 (en) | Use of pegylated recombinant human arginase for treatment of leukemia | |
| Dwivedy et al. | Engineering Novel DNA Nanoarchitectures for Targeted Drug Delivery and Aptamer Mediated Apoptosis in Cancer Therapeutics | |
| Kim et al. | Generation of iron-independent siderophore-producing Agaricus bisporus through the constitutive expression of hapX |